Navigation Links
PharmAthene Announces $3.9 Million Registered Direct Offering
Date:7/20/2010

ctual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; "will"; "project"; "potential"; or similar statements are forward-looking statements. PharmAthene disclaims any intent or obligation to update these forward-looking statements other than as required by law.  Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, technology transfer, and/or process validation of manufacturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC").

Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at www.PharmAthene.com.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. PharmAthene CEO To Participate on Biosecurity Panel at the 2010 BIO International Conference
2. PharmAthene Appoints Mitchel Sayare, Ph.D. to the Companys Board of Directors
3. PharmAthene Reports Year-End 2009 Financial and Operational Results and Provides Update On Ongoing Litigation With SIGA Technologies
4. PharmAthene to Provide Update on SparVax(TM) Contract Modification Suspension During Year-End 2009 Financial and Operational Results Conference Call on Tuesday March 23, 2010
5. PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010
6. PharmAthene to Present at the 2010 Roth Capital Markets Growth Stock Conference on Monday, March 15, 2010
7. PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine
8. PharmAthene Appoints Jeffrey W. Runge, M.D. to the Companys Board of Directors
9. PharmAthene Announces Updated Time for Conference Call to Review BARDA rPA Decision
10. PharmAthene Reports Third Quarter 2009 Financial and Operational Results
11. PharmAthene Executives Featured in Anthrax Pathogen Training Video for U.S. Department of Homeland Security
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA ... disease. One of these latent viruses is the Epstein ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... by the theory, a study found that RA patients ... (1). , What is Microcompetition? , Dr. Hanan ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... of high throughput research solutions, today announced that ... companies, has received delivery of Freeslate’s CM ... form screening. , Lupin, headquartered in Mumbai, ... quality, affordable generic and branded formulations and Active ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, ... Foundation, the only national nonprofit organization solely dedicated to ... quality of life for those affected worldwide, will host ... Warrington Country Club in Warrington, Pa. , Each ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider ... major scientific, regulatory, business, and media events in ... , today announced its former associate Virginia Cox , ... office. Virginia Cox re-joins ... Commissioner for the Office of External Affairs at the U.S. ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... ... initiative to create the next generation of fertilizers and production technologies, with initial financial ... ... -- IFDC is launching the Virtual Fertilizer Research Center (VFRC), a global ...
... , ... ... ... , ...
... ... ... ... ...
Cached Biology Technology:IFDC Launches Virtual Fertilizer Research Center 2IFDC Launches Virtual Fertilizer Research Center 3IFDC Launches Virtual Fertilizer Research Center 4IFDC Launches Virtual Fertilizer Research Center 5Icahn Nominates 4 to Genzyme Slate 2Icahn Nominates 4 to Genzyme Slate 3Icahn Nominates 4 to Genzyme Slate 4Icahn Nominates 4 to Genzyme Slate 5Icahn Nominates 4 to Genzyme Slate 6Icahn Nominates 4 to Genzyme Slate 7Icahn Nominates 4 to Genzyme Slate 8Icahn Nominates 4 to Genzyme Slate 9Icahn Nominates 4 to Genzyme Slate 10Longhorn Vaccines & Diagnostics LLC Receives FDA Emergency Use Authorization (EUA) for the First 2009 H1N1 Influenza Assay to Include a Molecular Transport Medium (MTM) 2Longhorn Vaccines & Diagnostics LLC Receives FDA Emergency Use Authorization (EUA) for the First 2009 H1N1 Influenza Assay to Include a Molecular Transport Medium (MTM) 3Longhorn Vaccines & Diagnostics LLC Receives FDA Emergency Use Authorization (EUA) for the First 2009 H1N1 Influenza Assay to Include a Molecular Transport Medium (MTM) 4Longhorn Vaccines & Diagnostics LLC Receives FDA Emergency Use Authorization (EUA) for the First 2009 H1N1 Influenza Assay to Include a Molecular Transport Medium (MTM) 5Longhorn Vaccines & Diagnostics LLC Receives FDA Emergency Use Authorization (EUA) for the First 2009 H1N1 Influenza Assay to Include a Molecular Transport Medium (MTM) 6
(Date:4/16/2014)... U.S. and beyond will convene in Lincoln, Nebraska, USA, ... existing science, and explore the unique geologic and historic ... applied geology, paleontology, and mid-continent geology. Events include a ... Kirk Johnson, Sant Director of the Smithsonian National Museum ... by the University of Nebraska-Lincoln. Lincoln is located near ...
(Date:4/16/2014)... Our ability to store memories improves during childhood, ... its connections with prefrontal and parietal cortices. New ... brain regions develop at this crucial time. Eventually, ... emerge in the transition into and during adolescence ... , Located deep in the middle of the ...
(Date:4/16/2014)... Martin Prechtl, Leo Heim and their colleagues at the ... new method of generating hydrogen using water and formaldehyde. ... interest when it comes to fuel cell technologies. The ... production using water and formaldehyde", have recently been published ... other applications, the new approach can be used to ...
Breaking Biology News(10 mins):Walking with mammoths and exploring mid-continental geology 2Walking with mammoths and exploring mid-continental geology 3Walking with mammoths and exploring mid-continental geology 4How kids' brain structures grow as memory develops 2
... the diaphragm muscles has received approval from the Food and ... Sclerosis (ALS), also known as Lou Gehrig,s disease. The ... patients breathe longer without the aid of a ventilator. ... Medical Center who helped develop and test DPS and who ...
... in the October 2011 print issue of The FASEB ... what kicks off the process that causes varicose veins. In ... binds to DNA to control gene function (called "transcription factor ... of proteins that significantly affect the development of varicose veins. ...
... work of a team of scientists at Cold Spring Harbor ... way to overcome one of the major technical obstacles preventing ... addressed successfully by novel drugs. The target is ... long known to be an important player in the signaling ...
Cached Biology News:Diaphragm pacing system receives FDA approval for use with ALS patients 2Scientists discover the proteins that control development of varicose veins 2Powerful antibody-based strategy suggests a new therapeutic approach to diabetes and obesity 2Powerful antibody-based strategy suggests a new therapeutic approach to diabetes and obesity 3Powerful antibody-based strategy suggests a new therapeutic approach to diabetes and obesity 4